75.92 +0.31 (0.41%)
Before hours: 4:45AM EDT
|Bid||0.00 x 900|
|Ask||75.99 x 900|
|Day's Range||74.93 - 77.00|
|52 Week Range||60.89 - 85.97|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||19.41|
|Earnings Date||Jul. 28, 2020 - Aug. 03, 2020|
|Forward Dividend & Yield||2.72 (3.60%)|
|Ex-Dividend Date||Jun. 11, 2020|
|1y Target Est||80.67|
Gilead Sciences Inc <GILD.O> plans to make more of its drug remdesivir available for Germany and Europe from autumn and will decide how much each country gets based on the rate of infection, the drugmaker's Germany boss told a German magazine. Bettina Bauer, managing director of Gilead in Germany, told WirtschaftsWoche the U.S. drugmaker can increase its worldwide monthly production from currently 190,000 treatment cycles to 2 million treatment cycles in December.
Gilead Sciences Inc plans to make more of its drug remdesivir available for Germany and Europe from the Fall and will decide how much each country gets based on the rate of infection, the drugmaker's Germany boss told a German magazine. Bettina Bauer, German managing director of Gilead, told WirtschaftsWoche the U.S. drugmaker can increase its worldwide monthly production from currently 190,000 treatment cycles to two million treatment cycles in December. Remdesivir is currently the only drug granted a conditional marketing authorisation by the EU for its use in COVID-19 patients.
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally. Cipla had earlier said pricing would not exceed 5,000 rupees. On Tuesday, Sovereign Pharma, which is manufacturing and packaging the drug for Cipla, said it had dispatched the first batch.
South Korea has asked Gilead Sciences Inc's to supply enough of its anti-viral drug remdesivir to treat more than 5,000 COVID-19 patients in preparation for a potential second wave of infections, an opposition lawmaker said on Wednesday. One of the few treatments shown to alter the course of COVID-10, remdesivir is in high demand, but there are concerns about its availability after Gilead allocated nearly all of its supply to the United States over the next three months. In a letter sent to Gilead on June 3, South Korea had requested doses for 360 patients who are in urgent need of the drug, and for enough to have ready for an additional 5,000 patients in the event of a second wave of infections.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data presented at the 23rd International AIDS Conference (AIDS 2020: Virtual) evaluating the impact of COVID-19 shelter-in-place orders (SIPOs) and PrEP utilization on HIV prevention strategies and associated risk behaviors. Findings presented included results from an online survey conducted by The American Academy of HIV Medicine (AAHIVM) to understand potential changes in behavior among pre-exposure prophylaxis (PrEP) users and prescribers in the United States during the height of COVID-19 SIPOs. There were 598 total respondents – 409 PrEP users and 189 PrEP prescribers. While most prescribers (90 percent) reported recommending no change in PrEP regimen, about one-third (33 percent) of PrEP users discontinued therapy voluntarily, mostly (85 percent) due to low perceived HIV risk associated with decreased sexual activity. Only 8 percent of those users who discontinued PrEP cited inability to access PrEP medications. Nearly all prescribers (95 percent) were able to successfully prescribe PrEP despite limitations caused by SIPOs.
Gilead Sciences (GILD) closed the most recent trading day at $76.42, moving -0.44% from the previous trading session.
India's Sovereign Pharma said it has dispatched the first batch of generic remdesivir for drugmaker Cipla Ltd, as the country recorded more than 22,000 new coronavirus cases on Tuesday. At current capacity, Sovereign can supply 50,000 to 95,000 vials per month of the injectable, the company said in an emailed statement on Tuesday. It did not disclose how many vials are there in the batch for Cipla.
Lilly's (LLY) shares are up this year mainly due to rapid progress in its efforts to make medicines/antibodies to treat COVID-19.
Zacks.com featured highlights include: Bristol-Myers Squibb, Vale, Gilead Sciences, Kroger and Delek Logistics Partners
Britain's GSK said on Tuesday that an injection of its cabotegravir drug given every two months was found to be 66% more effective in preventing HIV infections than Gilead's Truvada daily oral pills. HIV incidence rate - or the number of people who contract the infection in a period - was 0.41% with the injection, compared with 1.22% with Gilead's Truvada, final data from a study presented at the virtual AIDS conference showed. Truvada is currently the standard of care for preventing HIV, but GSK hopes to challenge its dominance by making shorter, long-lasting regimens and less toxic alternatives through its ViiV Healthcare unit.
Cases of coronavirus continue to rise in the United States, with states breaking daily records and no clear insight into how to curve the outbreak. Yahoo Finance’s Anjalee Khemlani breaks down the latest news about the coronavirus on The Final Round.
Earnings yield is very important in comparing a stock with other stocks and with fixed income securities. A stock with higher earnings yield fetches better returns.
Germany has only a few hundred doses of COVID-19 antiviral remdesivir, the country's health minister Jens Spahn told European Union lawmakers on Monday, urging to move production of the drug to Europe. "We do not have a huge inventory now, (it's) a few hundred doses that we have," he said at a video-conference hearing organised by the European Parliament. Spahn said he was working to ensure the drug could be produced in Europe.
Gilead (GILD) gets conditional marketing authorization for Veklury (remdesivir) as a treatment for SARS-CoV-2 infection by the European Commission.
Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at 4,800 rupees ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country. The Drug Controller General of India (DCGI) approved Mylan's remdesivir version, to be called Desrem, for the treatment of suspected or laboratory confirmed severe incidences of COVID-19 in adults and children, the company said in a statement https://prn.to/2By83B9. Mylan's version comes after two Indian drugmakers, Cipla Ltd and privately-held Hetero Labs Ltd, launched their generic versions of the drug.
The World Health Organization (WHO) said on Saturday that it was discontinuing its trials of the malaria drug hydroxychloroquine and combination HIV drug lopinavir/ritonavir in hospitalised patients with COVID-19 after they failed to reduce mortality. The U.N. agency said that the decision, taken on the recommendation of the trial's international steering committee, does not affect other studies where the drugs are used for non-hospitalised patients or as a prophylaxis. Another arm of the WHO-led trial is looking at the potential effect of Gilead's antiviral drug remdesivir on COVID-19.
At the end of April, shares of Gilead Sciences (NASDAQ: GILD) were hovering near their 52-week highs of $85.97. The stock has been falling since then, and it's now trading at just about $76. Year to date, the stock is still up 17%, and well above the 4% decline the S&P 500 has seen during the same period.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data demonstrating the safety and efficacy of the once-daily, single tablet regimen Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in virologically suppressed adults ages 65 and older (n=140), including those with common comorbidities such as diabetes (22 percent), hypertension (55 percent), cardiovascular disease (24 percent), and dyslipidemia, which is an abnormal amount of lipids in the blood (59 percent). At 48 weeks, 92 percent of those who switched to Biktarvy maintained virologic suppression, achieving HIV RNA<50 copies/mL. Across the studies, Biktarvy was generally well tolerated. These data were evaluated as part of a pooled analysis of four international trials and will be presented during the 23rd International AIDS Conference (AIDS 2020: Virtual).
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from an ongoing Phase 1 study, which showed that a sustained-delivery subcutaneous formulation of the company’s investigational, novel inhibitor of HIV-1 capsid function, lenacapavir (GS-6207), sustained predicted therapeutic concentrations for at least six months following a single 900 mg dose. In the study, lenacapavir was generally well-tolerated, and no serious adverse events were reported. These data were presented at the 23rd International AIDS Conference (AIDS 2020: Virtual).
Gilead Sciences just nabbed another huge potential customer for its drug remdesivir. The European Commission said Friday it had granted its conditional approval for the use of the antiviral drug in severe COVID-19 patients. That makes it the region's first authorized therapy to treat the virus. The U.S. has already cleared it for emergency use. Gilead said Japan, Taiwan, India, Singapore and the UAE have also approved it as a COVID-19 therapy. Remdesivir is in high demand because it helped shorten hospital recovery times in a clinical trial. Administered intravenously, the drug is generally being used on patients sick enough to require hospitalization. Gilead has allocated nearly all of its supply to the U.S over the next three months. The Commission said it's in talks with Gilead to get doses for the 27 European Union countries.
The European Commission has granted conditional approval to Veklury, the antiviral known as remdesivir.
Shares of Gilead Sciences (NASDAQ: GILD) rose 18.4% the first half, according to data provided by S&P Global Market Intelligence, as hospitals began using its drug remdesivir to treat COVID-19 patients. Early into the health crisis, Gilead began testing remdesivir as a possible treatment for the illness caused by the novel coronavirus. More recently, remdesivir entered clinical trials for COVID-19, and as promising data emerged, the U.S. Food and Drug Administration granted the drug Emergency Use Authorization.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted conditional marketing authorization for Veklury® (remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. The conditional marketing authorization was granted in the interest of public health due to the COVID-19 pandemic and was based on a rolling review of supporting data that began in April 2020.